|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Bcl2 genotypes were marginally associated overall with breast cancer risk.
|
22320961 |
2011 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
AA genotype of BCL2-938C>A polymorphism might influence BCL2 gene expression there by associated with elevated risk for breast cancer progression.
|
26662799 |
2016 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
B-cell lymphoma 2 (BCL2) family is the most important regulator of apoptosis, and -938C>A single nucleotide polymorphism (SNP) of <i>BCL2</i> gene promoter has been demonstrated to influence breast cancer susceptibility.
|
28413418 |
2017 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To gain insight into the molecular mechanisms involved in human prolactin receptor antagonist (hPRL-G129R)-induced apoptosis, we used real-time reverse transcription-polymerase chain reaction to measure bax and bcl-2 gene expression in 11 human breast cancer cell lines following treatment with hPRL and hPRL-G129R.
|
14647416 |
2004 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The topics include (i) repair mechanisms of heavy ion-induced DNA damage, (ii) superior effects of heavy ions on radioresistant tumor cells (intratumor quiescent cell population, TP53-mutated and BCL2-overexpressing tumors), (iii) novel capacity of heavy ions in suppressing cancer metastasis and neoangiogenesis, and (iv) potential of heavy ions to induce secondary (especially breast) cancer.
|
20679739 |
2010 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our study suggests a role of genetic variation in BIRC5, BCL2 and CLU as progression and prognostic markers for BC, supporting previous studies based on the expression of the genes.
|
22037783 |
2012 |
|
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Ki-67, p53 and BCL-2 Expressions and their Association with Clinical Histopathology of Breast Cancer among Women in Tanzania.
|
31289309 |
2019 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Angiopoietin-2, an angiogenic regulator, promotes initial growth and survival of breast cancer metastases to the lung through the integrin-linked kinase (ILK)-AKT-B cell lymphoma 2 (Bcl-2) pathway.
|
21680733 |
2011 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tea phytoconstituents are known to modulate myriad molecular events which include prominent regulators of intracellular signaling, such as phosphatidylinositide 3-kinase/protein kinase B/nuclear factor-κB, epidermal growth factor receptor, vascular endothelial growth factor, B-cell lymphoma 2 (Bcl-2) and Bcl-2 associated X protein in the development and progression of breast carcinoma.
|
28396252 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
More recently, Bcl-2 has been recognized as an important prognostic factor in breast cancer, although controversies persist with respect to the significance of its expression.
|
28801774 |
2017 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bcl2 is an important prognostic parameter in human breast cancer.
|
17372162 |
2007 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Prognostic value of apoptosis in breast cancer (pT1-pT2). A TUNEL, p53, bcl-2, bag-1 and Bax immunohistochemical study.
|
15168338 |
2004 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chemosensitization of breast carcinoma cells with the use of bcl-2 antisense oligodeoxynucleotide.
|
15177426 |
2004 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Borrelidin has limited anti-cancer effects in bcl-2 overexpressing breast cancer and leukemia cells and reveals toxicity in non-malignant breast epithelial cells.
|
24155182 |
2014 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
|
12174951 |
2002 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
There was significant co-expression of TFF3 with AKT1 (p = 0.0365), BCl2 (p = 0.0152), and NF Kappa-B (p = 0.0243) in breast carcinoma cases with residual carcinoma following neoadjuvant therapy which support the role of TFF3 in chemoresistance.
|
30744593 |
2019 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, the effects of BCL-2 inhibitors on drug resistant breast cancer have not yet been elucidated.
|
29496539 |
2018 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Breast cancer in women aged less than 35 years also had higher histologic grade and higher frequency of bcl-2-negative tumor than that found in the 36- to 50-year age group.
|
12607598 |
2002 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The reduction of Bak may play important roles in malignant development of breast cancer to acquire estrogen independency, counteracting the reduced Bcl-2.
|
10800077 |
2000 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because anti-apoptotic BCL-2 family proteins can affect the threshold for induction of apoptosis and thus limit the effectiveness of the chemotherapeutic payload, we examined whether inhibition of BCL-2/X<sub>L</sub> would enhance the efficacy of T-DM1 in five HER2-expressing patient-derived breast cancer xenograft models.
|
30962322 |
2019 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Involvement of the mitochondrial pathway and Bim/Bcl-2 balance in dihydroartemisinin-induced apoptosis in human breast cancer in vitro.
|
23138847 |
2013 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The study results indicate that Bcl-2 and S-phase analysis of fine-needle samples of breast carcinomas provide a convenient tool for the assessment of these tumors.
|
11025483 |
2000 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study focuses on the effect of nicotine on the expressions of the α7 nicotinic receptor gene and Bax and Bcl-2 proteins in mammary gland epithelial-7 (MCF-7) breast cancer cells and its relationship to drug resistance.
|
26812869 |
2015 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Bcl-2, c-Myc and c-Jun does not only take part in cell death, but also in cell division in breast carcinoma cells in which the regulation of cell division and cell death are strictly connected.
|
11820644 |
2001 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
|
12632082 |
2003 |